Dermatomycoses - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Dermatomycoses - Pipeline Review, H1 2016', provides an overview of the Dermatomycoses pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dermatomycoses, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dermatomycoses and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Dermatomycoses - The report reviews pipeline therapeutics for Dermatomycoses by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Dermatomycoses therapeutics and enlists all their major and minor projects - The report assesses Dermatomycoses therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Dermatomycoses Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Dermatomycoses - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Dermatomycoses pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Dermatomycoses Overview 6 Therapeutics Development 7 Pipeline Products for Dermatomycoses - Overview 7 Pipeline Products for Dermatomycoses - Comparative Analysis 8 Dermatomycoses - Therapeutics under Development by Companies 9 Dermatomycoses - Therapeutics under Investigation by Universities/Institutes 10 Dermatomycoses - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Unknown Stage Products 14 Dermatomycoses - Products under Development by Companies 15 Dermatomycoses - Products under Investigation by Universities/Institutes 16 Dermatomycoses - Companies Involved in Therapeutics Development 17 Anacor Pharmaceuticals, Inc. 17 Blueberry Therapeutics Ltd 18 Daewoong Pharmaceutical Co., Ltd. 19 Helix BioMedix, Inc. 20 TGV-Laboratories 21 Viamet Pharmaceuticals, Inc. 22 Dermatomycoses - Therapeutics Assessment 23 Assessment by Monotherapy Products 23 Assessment by Target 24 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 AN-2718 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 BB-2603 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 dapaconazole - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 DWP-06081 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 HB-1275 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Myc-102 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Small Molecule for Fungal Infections - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 VT-1161 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Dermatomycoses - Recent Pipeline Updates 41 Dermatomycoses - Dormant Projects 45 Dermatomycoses - Product Development Milestones 46 Featured News & Press Releases 46 Jul 09, 2014: Viamet Reports Additional Positive Interim Results of Phase 2 Studies of VT-1161 with Moderate to Severe Interdigital Tinea Pedis 46 Mar 12, 2014: Viamet Reports Positive Interim Results of Phase 2 Interdigital Tinea Pedis Study of VT-1161 46 Appendix 48 Methodology 48 Coverage 48 Secondary Research 48 Primary Research 48 Expert Panel Validation 48 Contact Us 48 Disclaimer 49
List of Tables
Number of Products under Development for Dermatomycoses, H1 2016 7 Number of Products under Development for Dermatomycoses - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Development, H1 2016 13 Comparative Analysis by Unknown Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Dermatomycoses - Pipeline by Anacor Pharmaceuticals, Inc., H1 2016 17 Dermatomycoses - Pipeline by Blueberry Therapeutics Ltd, H1 2016 18 Dermatomycoses - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016 19 Dermatomycoses - Pipeline by Helix BioMedix, Inc., H1 2016 20 Dermatomycoses - Pipeline by TGV-Laboratories, H1 2016 21 Dermatomycoses - Pipeline by Viamet Pharmaceuticals, Inc., H1 2016 22 Assessment by Monotherapy Products, H1 2016 23 Number of Products by Stage and Target, H1 2016 25 Number of Products by Stage and Mechanism of Action, H1 2016 27 Number of Products by Stage and Route of Administration, H1 2016 29 Number of Products by Stage and Molecule Type, H1 2016 31 Dermatomycoses Therapeutics - Recent Pipeline Updates, H1 2016 41 Dermatomycoses - Dormant Projects, H1 2016 45
List of Figures
Number of Products under Development for Dermatomycoses, H1 2016 7 Number of Products under Development for Dermatomycoses - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Products, H1 2016 13 Assessment by Monotherapy Products, H1 2016 23 Number of Products by Targets, H1 2016 24 Number of Products by Stage and Targets, H1 2016 24 Number of Products by Mechanism of Actions, H1 2016 26 Number of Products by Stage and Mechanism of Actions, H1 2016 26 Number of Products by Routes of Administration, H1 2016 28 Number of Products by Stage and Routes of Administration, H1 2016 28 Number of Products by Molecule Types, H1 2016 30 Number of Products by Stage and Molecule Types, H1 2016 30
Global automotive collision repair market is expected to be valued at USD 196.97 billion by 2020, as per a new research report by Radiant Insights, Inc. The industry is expected to witness significant growth owing to increasing number of on-road vehiRead More...
Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expectedRead More...
Global advanced energy storage systems market size is anticipated to be valued at USD 24.8 billion by 2022, as per a new research report by Radiant Insights, Inc. Increasing energy consumption coupled with strong energy demand for industrial, commercRead More...
Europe industrial air filtration market size is projected to reach USD 1,690.8 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing implementation in various industries such as metal, cement and food & beverages among otRead More...
Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous industRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.